阿巴西普用于非亲缘供者造血细胞移植后急性移植物抗宿主病预防
基于国际血液与骨髓移植研究中心数据,分析2011至2018年接受7/8 HLA不合或8/8 HLA相合非亲缘供者移植患者,阿巴西普联合钙调神经磷酸酶抑制剂/甲氨蝶呤较单用该方案及联合抗胸腺细胞球蛋白改善生存,与移植后环磷酰胺方案相似。
要点
- 7/8 HLA不合移植中,阿巴西普联合方案180天总生存98% vs 单用75%(P=0.0028)。
- 7/8 HLA不合移植中,阿巴西普联合方案2年无复发生存74% vs 单用49%(P=0.0098)。
- 8/8 HLA相合移植中,阿巴西普联合方案2年无复发生存风险比0.46(0.25-0.86)较单用改善。
核心结论
- 在7/8 HLA不合和8/8 HLA相合非亲缘供者移植中,阿巴西普联合钙调神经磷酸酶抑制剂/甲氨蝶呤较单用该方案及联合抗胸腺细胞球蛋白改善生存结局,与移植后环磷酰胺方案相似。
- 阿巴西普联合钙调神经磷酸酶抑制剂/甲氨蝶呤可能有助于扩大非亲缘供者移植的供者池。
研究设计与样本
- 利用国际血液与骨髓移植研究中心数据,分析2011至2018年接受7/8 HLA不合或8/8 HLA相合非亲缘供者造血细胞移植的患者。
- 比较阿巴西普联合钙调神经磷酸酶抑制剂/甲氨蝶呤与单用钙调神经磷酸酶抑制剂/甲氨蝶呤、联合抗胸腺细胞球蛋白及基于移植后环磷酰胺的预防方案。
主要发现
- 7/8 HLA不合移植中,180天总生存阿巴西普联合方案98% vs 单用75%(P=0.0028)。
- 7/8 HLA不合移植中,2年无复发生存阿巴西普联合方案74% vs 单用49%(P=0.0098),vs 联合抗胸腺细胞球蛋白77% vs 35%(P=0.0002),vs 移植后环磷酰胺72% vs 56%(P=0.1058)。
关键数值与推荐
- 7/8 HLA不合移植中,180天总生存阿巴西普联合方案98% vs 单用75%(P=0.0028)。
- 7/8 HLA不合移植中,2年无复发生存阿巴西普联合方案74% vs 单用49%(P=0.0098),vs 联合抗胸腺细胞球蛋白77% vs 35%(P=0.0002),vs 移植后环磷酰胺72% vs 56%(P=0.1058)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). Using Center for International Blood and Marrow Transplant Research data, we investigated its impact in patients receiving 7/8 HLA-mismatched unrelated donor (MMUD) or 8/8 HLA-matched unrelated donor (MUD) URD-HCT between 2011 and 2018. Primary outcomes included day-180, 1-year, and 2-year overall survival (OS) and relapse-free survival (RFS) for abatacept + CNI/MTX vs CNI/MTX, CNI/MTX + antithymocyte globulin (ATG), and posttransplant cyclophosphamide-based prophylaxis (PT-Cy). For 7/8 MMUDs, day-180 OS (primary end point supporting FDA approval) was significantly higher for abatacept + CNI/MTX vs CNI/MTX (98% vs 75%; P = .0028). Two-year RFS was significantly higher for abatacept + CNI/MTX vs CNI/MTX (74% vs 49%; P = .0098) and CNI/MTX + ATG (77% vs 35%; P = .0002), and similar vs PT-Cy (72% vs 56%; P = .1058). For 8/8 MUDs, 2-year RFS for abatacept + CNI/MTX was numerically higher vs CNI/MTX (63% vs 52%; P = .1497), with an improved hazard ratio (HR) of 0.46 (0.25-0.86), and vs CNI/MTX + ATG (66% vs 55%; P = .1193; HR, 0.39 [0.21-0.73]), and was similar vs PT-Cy (68% vs 57%; P = .2356; HR, 0.54 [0.26-1.11]). For 7/8 MMUD and 8/8 MUD recipients, abatacept + CNI/MTX prophylaxis improved survival outcomes vs CNI/MTX and CNI/MTX + ATG; outcomes were similar to PT-Cy-based regimens. Abatacept + CNI/MTX may facilitate unrelated donor pool expansion for HCT.
引用
- Kean LS, Burns LJ, Kou TD, et al. Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation. Blood. 2024. PMID: 39028876. doi:10.1182/blood.2023023660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。